Literature DB >> 25713780

Recurrence of papillary thyroid cancer after optimized surgery.

Clive S Grant1.   

Abstract

Recurrence of papillary thyroid cancer (PTC) after optimized surgery requires a full understanding of the disease, especially as it has changed in the last 15 years, what comprises optimized surgery, and the different types and implications of disease relapse that can be encountered. PTC has evolved to tumors that are much smaller than previously seen, largely due to various high quality imaging studies obtained for different reasons, but serendipitously identifying thyroid nodules that prove to be papillary thyroid microcarcinomas (PTMC). With rare exception, these cancers are cured by conservative surgery without additional therapy, and seldom result in recurrent disease. PTC is highly curable in 85% of cases because of its rather innocent biologic behavior. Therefore, the shift in emphasis from disease survival to recurrence is appropriate. As a result of three technologic advances-high-resolution ultrasound (US), recombinant TSH, and highly sensitive thyroglobulin (Tg)-disease relapse can be discovered when it is subclinical. Endocrinologists who largely control administration of radioactive iodine have used it to ablate barely detectable or even biochemically apparent disease, hoping to reduce recurrence and perhaps improve survival. Surgeons, in response to this new intense postoperative surveillance that has uncovered very small volume disease, have responded by utilizing US preoperatively to image this disease, and incorporated varying degrees of lymphadenectomy into their initial treatment algorithm. Bilateral thyroid resection-either total or near-total thyroidectomy-remains the standard for PTC >1 cm, although recent data has re-emphasized the value of unilateral lobectomy in treating even some PTC measuring 1-4 cm. Therapeutic lymphadenectomy has universal approval, but when lymph nodes in the central neck are not worrisome to the surgeon's intraoperative assessment, although that judgment in incorrect up to 50%, whether they should be excised has reached a central point of controversy. Disease relapse can occur individually or in combination of three different forms: lymph node metastasis (LNM), true soft tissue local recurrence, and distant disease. The latter two are worrisome for potentially life-threatening consequences whereas nodal metastases are often persistent from the initial operation, and mostly comprise a biologic nuisance rather than virulent disease. A moderate surgical approach of bilateral thyroid resection, with usual central neck nodal clearance, and lateral internal jugular lymphadenectomy for node-positive disease can be performed safely, and with about a 5% recurrence rate.

Entities:  

Keywords:  Papillary thyroid cancer (PTC); lymph nodes; recurrence; surgery

Year:  2015        PMID: 25713780      PMCID: PMC4321046          DOI: 10.3978/j.issn.2227-684X.2014.12.06

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  53 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

3.  Papillary carcinoma of the thyroid. I. Developing pattern of metastasis.

Authors:  S Noguchi; A Noguchi; N Murakami
Journal:  Cancer       Date:  1970-11       Impact factor: 6.860

4.  A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer.

Authors:  Aleksandra Popadich; Olga Levin; James C Lee; Stephanie Smooke-Praw; Kevin Ro; Maisam Fazel; Asit Arora; Neil S Tolley; Fausto Palazzo; Diana L Learoyd; Stan Sidhu; Leigh Delbridge; Mark Sywak; Michael W Yeh
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

5.  Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer.

Authors:  Mark Sywak; Lachlan Cornford; Paul Roach; Peter Stalberg; Stan Sidhu; Leigh Delbridge
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

6.  Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.

Authors:  John M Stulak; Clive S Grant; David R Farley; Geoffrey B Thompson; Jon A van Heerden; Ian D Hay; Carl C Reading; J William Charboneau
Journal:  Arch Surg       Date:  2006-05

7.  Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.

Authors:  K C Loh; F S Greenspan; L Gee; T R Miller; P P Yeo
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

8.  Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience.

Authors:  E Baudin; J P Travagli; J Ropers; F Mancusi; G Bruno-Bossio; B Caillou; A F Cailleux; J D Lumbroso; C Parmentier; M Schlumberger
Journal:  Cancer       Date:  1998-08-01       Impact factor: 6.860

9.  Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism.

Authors:  E Lundgren; S Ljunghall; G Akerström; J Hetta; H Mallmin; J Rastad
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

10.  Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases.

Authors:  Kenichi Matsuzu; Kiminori Sugino; Katsuhiko Masudo; Mitsuji Nagahama; Wataru Kitagawa; Hiroshi Shibuya; Keiko Ohkuwa; Takashi Uruno; Akifumi Suzuki; Syunsuke Magoshi; Junko Akaishi; Chie Masaki; Michikazu Kawano; Nobuyasu Suganuma; Yasushi Rino; Munetaka Masuda; Kaori Kameyama; Hiroshi Takami; Koichi Ito
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

View more
  44 in total

1.  Distinguishing Recurrent Thyroid Cancer from Residual Nonmalignant Thyroid Tissue Using Multiphasic Multidetector CT.

Authors:  J M Debnam; N Guha-Thakurta; J Sun; W Wei; M E Zafereo; M E Cabanillas; N M Buisson; D Schellingerhout
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-23       Impact factor: 3.825

2.  MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.

Authors:  Adriana Sondermann; Flavia Maziero Andreghetto; Ana Carolina Bernardini Moulatlet; Elivane da Silva Victor; Marilia Germanos de Castro; Fábio Daumas Nunes; Lenine Garcia Brandão; Patricia Severino
Journal:  Clin Exp Metastasis       Date:  2015-05-26       Impact factor: 5.150

3.  Expression of autophagy-associated proteins in papillary thyroid carcinoma.

Authors:  Meiliu Yang; Lu Bai; Wu Yu; Xueling Sun; Gang Xu; Ruhua Guan; Ying Yang; Mingyue Qiu; Yazhong Zhang; Jinli Tian; Hui Fang
Journal:  Oncol Lett       Date:  2017-04-28       Impact factor: 2.967

4.  Radioguided occult lesion localization in patients with recurrent thyroid cancer.

Authors:  Murat Tuncel; Nilda Süslü
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-18       Impact factor: 2.503

5.  miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.

Authors:  Rui Li; Jia Liu; Qun Li; Guang Chen; Xiaofang Yu
Journal:  Tumour Biol       Date:  2015-10-19

6.  Total tumor diameter: the neglected value in papillary thyroid microcarcinoma.

Authors:  J-W Feng; H Pan; L Wang; J Ye; Y Jiang; Z Qu
Journal:  J Endocrinol Invest       Date:  2019-11-20       Impact factor: 4.256

7.  Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015).

Authors:  Ian D Hay; Tammi R Johnson; Suneetha Kaggal; Megan S Reinalda; Nicole M Iniguez-Ariza; Clive S Grant; Siobhan T Pittock; Geoffrey B Thompson
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

8.  Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?

Authors:  Kyujin Han; Hae Min Noh; Ha Min Jeong; Young Chang Lim
Journal:  Ann Surg Oncol       Date:  2021-05-27       Impact factor: 5.344

9.  Recurrent Papillary Thyroid Carcinoma to the Cervical Lymph Nodes: Outcomes of Compartment-Oriented Lymph Node Resection.

Authors:  Carlos Gustavo Rivera-Robledo; David Velázquez-Fernández; Juan Pablo Pantoja; Mauricio Sierra; Bernardo Pérez-Enriquez; Raul Rivera-Moscoso; Mónica Chapa; Miguel F Herrera
Journal:  World J Surg       Date:  2019-11       Impact factor: 3.352

10.  Serum TSH levels are associated with postoperative recurrence and lymph node metastasis of papillary thyroid carcinoma.

Authors:  Yingying Xiang; Yiying Xu; Adheesh Bhandari; Namita Sindan; Suzita Hirachan; Qing Yang; Guilong Guo; Yanyan Shen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.